Sanofi SA (SNY)

38.04
NYSE : Health Care
Prev Close 38.04
Day Low/High 0.00 / 0.00
52 Wk Low/High 37.41 / 51.88
Avg Volume 2.46M
Exchange NYSE
Shares Outstanding 2.57B
Market Cap 98.72B
EPS 1.90
P/E Ratio 20.62
Div & Yield 1.66 (4.30%)

Latest News

Sanofi Fighting a Losing Battle, Sues Merck for Alleged Patent Infrigement

Sanofi Fighting a Losing Battle, Sues Merck for Alleged Patent Infrigement

Allegations that Merck breached patents on diabetes blockbuster Lantus looks like a replay of Sanofi's 2015 case against Eli Lilly.

5 Things You Must Know Before the Market Opens Monday

5 Things You Must Know Before the Market Opens Monday

U.S. stock futures point higher as oil prices rally; Canada's autoworkers' union and GM make little progress in contract talks ahead of a Monday deadline.

Stephen King's Maximum Oversold (by Midweek)

And we'll get FOMC and BoJ then.

Treatment Effects Maintained Over Six Years In Patients With Relapsing Remitting Multiple Sclerosis Who Received Sanofi Genzyme's Lemtrada® (alemtuzumab) In Clinical Trials

Treatment Effects Maintained Over Six Years In Patients With Relapsing Remitting Multiple Sclerosis Who Received Sanofi Genzyme's Lemtrada® (alemtuzumab) In Clinical Trials

Sanofi and its specialty care global business unit Sanofi Genzyme announced today positive new six-year investigational data from the extension study of Lemtrada ® (alemtuzumab) in patients with relapsing...

Results From 1,000-Patient, Global Real-World Patient-Reported Outcomes Study Of Sanofi Genzyme's Aubagio® (teriflunomide) In Patients With Relapsing Multiple Sclerosis Demonstrate High Levels Of Treatment Satisfaction

Results From 1,000-Patient, Global Real-World Patient-Reported Outcomes Study Of Sanofi Genzyme's Aubagio® (teriflunomide) In Patients With Relapsing Multiple Sclerosis Demonstrate High Levels Of Treatment Satisfaction

Sanofi Genzyme, the specialty care global business unit of Sanofi, today announced positive new real-world data from the Phase 4 Teri-PRO (Patient Reported Outcomes) study of Aubagio ®  (teriflunomide), a...

Mylan Still Isn't Cheap

Mylan Still Isn't Cheap

The EpiPen controversy makes this stock a shot in the dark.

EpiPen Price Relief Could Come From Rivals Before Politicians

EpiPen Price Relief Could Come From Rivals Before Politicians

Mylan's EpiPen continues to dominate the market as a one-time rival looks to come back.

Relief From EpiPen's Stranglehold May Come From Rivals Before Politicians

Relief From EpiPen's Stranglehold May Come From Rivals Before Politicians

Mylan's EpiPen continues to dominate the market as a one-time rival looks to come back.

John Paulson Bought These 5 Stocks -- but the Charts Say Sell

John Paulson Bought These 5 Stocks -- but the Charts Say Sell

How does technical analysis stack up to John Paulson's stock picking strategy?

Beat Up on the Corporations This Election Year; Market Helping Consumer: Jim Cramer's Best Blogs

Beat Up on the Corporations This Election Year; Market Helping Consumer: Jim Cramer's Best Blogs

Jim Cramer ponders the presidential campaign tradition of corporate bashing and how the stock market is more important than the Fed.

Bearish Bets: A Broadcasting Firm, a Precious-Metals Name and Other Stocks That Look Good Short

TGNA, AMRK, FBRC, FLO and SNY were all recently downgraded by TheStreet's Quant Ratings.

Cramer: It's a Presidential Campaign, So Let the Corporate Bashing Begin

Cramer: It's a Presidential Campaign, So Let the Corporate Bashing Begin

Clinton goes after the drug companies again -- for starters.

Mylan Falls After Being Called Out on Price Increases -- Should You Worry?

Mylan Falls After Being Called Out on Price Increases -- Should You Worry?

Shares of the world's second largest generic pharma company fell nearly 5% after U.S. politicians target company for price gouging.

10 Stocks Billionaire John Paulson Is Buying for 2016

10 Stocks Billionaire John Paulson Is Buying for 2016

Here are 10 stocks hedge fund manager John Paulson has been buying lately, either initiating new stakes or upping his holdings significantly.

Analysts' Actions -- Abbott Labs, Garmin, Nordson, NetApp and More

Analysts' Actions -- Abbott Labs, Garmin, Nordson, NetApp and More

Here are Wednesday's top research calls, including upgrades for Abbott Labs and NetApp, and downgrades for Garmin and Nordsom.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABT, AXLL, BOKF, FLY, KCAP, RWC Downgrades: BBRG, CCOI, DL, EMG, FLO, HWBK, IIJI, INOD, MTH, NOA, SMCI, SNY, TGNA Initiations: BUFF, GI, NSA Read on to get TheStreet Quant Ratings' detailed report:

Medivation Scores Premium in Sale to Pfizer

Medivation Scores Premium in Sale to Pfizer

Shareholders of the oncology drug maker ought to be satisfied with the auction's conclusion.

Pfizer's Deal to Buy Medivation May Give the Company Its Groove Back

Pfizer's Deal to Buy Medivation May Give the Company Its Groove Back

Pfizer's $14 billion acquisition of Medivation is a strong purchase, according to Jim Cramer, who now wonders what Sanofi will do next.

Pfizer to Pick Up Medivation in All-Cash Deal

PFE is trading up on the announcement, and the deal should add to earnings in 2017.

Pfizer Is Buying Medivation for $14 Billion

Pfizer Is Buying Medivation for $14 Billion

Pfizer confirmed its $14 billion acquisition of cancer drugmaker Medivation on Monday.

5 Things You Must Know Before the Market Opens Monday

5 Things You Must Know Before the Market Opens Monday

Pfizer finalizes a deal to buy cancer drugmaker Medivation; ChemChina gets U.S. approval for its takeover of Syngenta; Viacom CEO Philippe Dauman is ousted.

Pfizer Confirms $14 Billion Takeover of Cancer Drugmaker Medivation

Pfizer Confirms $14 Billion Takeover of Cancer Drugmaker Medivation

Acquiring Medivation will strengthen Pfizer's oncology franchise, which has lost ground in recent years to some Big Pharma competitors.

What CVS and Express Scripts' Drug Exclusion Lists Means for Your Portfolio

What CVS and Express Scripts' Drug Exclusion Lists Means for Your Portfolio

Earlier this month the two major pharmacy benefit managers, CVS Caremark CVS and Express Scripts ESRX released lists of drugs they will no longer cover in 2017.

Biotech Pop-Up Party in Full Swing

Biotech Pop-Up Party in Full Swing

The beaten-down biotech sector is making an impressive comeback. The sector seems to be rebounding after tumbling by more than 40%.

It's 'All Systems Go' for Biotech

It's 'All Systems Go' for Biotech

The sector seems to be rebounding after tumbling by more than 40%.

Pokèmon Go Reflects the Increasingly Lucrative Business of Mobile Gaming

Pokèmon Go Reflects the Increasingly Lucrative Business of Mobile Gaming

The alternate reality mobile gaming app has been downloaded over 75 million times in less than a month.

Pokèmon Go Is Just the Tip of the Mobile-Gaming Iceberg

Pokèmon Go Is Just the Tip of the Mobile-Gaming Iceberg

The mobile-gaming market is expected to surpass console games this year, according to Deloitte.